Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2006

View Archived Issues

Shire recaps year's successes

Incyte makes considerable progress in fourth quarter

Enrollment completed in first of two phase III studies of AI-700

Digna Biotech and Biotherapix to develop treatment for pulmonary fibrosis

Novo Nordisk reinitiates phase III program for AERx iDMS

Enrollment completed in phase I study of AdPEDF gene therapy

Enrollment open in phase I study of BSI-201 for advanced malignancies

Phase II study of DP-b99 in acute stroke cleared to continue

Baxter opens phase II adult stem cell therapy trial for chronic myocardial ischemia

Juvaris awarded SBIR grant for HIV vaccine development

Quigley files IND for clinical trials of QR-333 in diabetic peripheral neuropathy

Positive results for Zegerid in nocturnal acid breakthrough

Nonapprovable letter for Vadova

Reveromycin A shows potential for osteoporosis

Kyorin's antidiabetic agent KRP-104 begins phase I

Shionogi and Galderma reach initial sales agreement for adapalene gel

N-Acetylcysteine: an antioxidant and MMP inhibitor for oral cancer

European approval for Remicade for ulcerative colitis

EM-011: Potential oral treatment of drug-resistant lymphomas

Novel agents imparted for the treatment of inflammatory disorders

Recent patents impart novel agents for obesity and lipoprotein disorders

Novel analgesic agents disclosed in recent patent literature

Promising results from phase I and II studies in prostate cancer

Preliminary clinical data on efalizumab for the treatment of oral lichen planus reported

Kaken reports preclinical data on its novel leukotriene/thromboxane dual inhibitor KP-496

New preclinical data on Chinese herbal medicine formula presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...